z-logo
Premium
Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis
Author(s) -
Schepke Michael,
Kleber Gerhard,
Nürnberg Dieter,
Willert Jörg,
Koch Lydia,
VeltzkeSchlieker Wilfried,
Hellerbrand Claus,
Kuth Johannes,
Schanz Stefan,
Kahl Stefan,
Fleig Wolfgang E.,
Sauerbruch Tilman
Publication year - 2004
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.20284
Subject(s) - medicine , ligation , cirrhosis , varices , propranolol , incidence (geometry) , gastroenterology , etiology , randomized controlled trial , surgery , esophageal varices , portal hypertension , physics , optics
In this randomized controlled multicenter trial, we compared endoscopic variceal banding ligation (VBL) with propranolol (PPL) for primary prophylaxis of variceal bleeding. One hundred fifty‐two cirrhotic patients with 2 or more esophageal varices (diameter >5 mm) without prior bleeding were randomized to VBL (n = 75) or PPL (n = 77). The groups were well matched with respect to baseline characteristics (age 56 ± 10 years, alcoholic etiology 51%, Child‐Pugh score 7.2 ± 1.8). The mean follow‐up was 34 ± 19 months. Data were analyzed on an intention‐to‐treat basis. Neither bleeding incidence nor mortality differed significantly between the 2 groups. Variceal bleeding occurred in 25% of the VBL group and in 29% of the PPL group. The actuarial risks of bleeding after 2 years were 20% (VBL) and 18% (PPL). Fatal bleeding was observed in 12% (VBL) and 10% (PPL). It was associated with the ligation procedure in 2 patients (2.6%). Overall mortality was 45% (VBL) and 43% (PPL) with the 2‐year actuarial risks being 28% (VBL) and 22% (PPL). 25% of patients withdrew from PPL treatment, 16% due to side effects. In conclusion , VBL and PPL were similarly effective for primary prophylaxis of variceal bleeding. VBL should be offered to patients who are not candidates for long‐term PPL treatment. (H EPATOLOGY 2004;40:65–72.)

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom